Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 2,348.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 342,418 shares of the company's stock after purchasing an additional 328,434 shares during the period. Geode Capital Management LLC owned 0.98% of Oruka Therapeutics worth $6,643,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of ORKA. Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares during the period. Franklin Resources Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter worth $17,661,000. Wellington Management Group LLP lifted its position in Oruka Therapeutics by 15.8% during the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after acquiring an additional 12,952 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at about $303,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $144,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ORKA. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target on the stock. Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $39.86.

Oruka Therapeutics Trading Up 1.7 %

ORKA traded up $0.17 on Tuesday, reaching $10.45. The stock had a trading volume of 167,125 shares, compared to its average volume of 236,490. The business's 50-day moving average price is $10.03 and its two-hundred day moving average price is $16.57. The company has a market cap of $391.26 million, a P/E ratio of -1.67 and a beta of 0.47. Oruka Therapeutics, Inc. has a 12-month low of $5.49 and a 12-month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19. As a group, analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insider Activity at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the transaction, the insider now owns 4,148,428 shares of the company's stock, valued at $47,458,016.32. This trade represents a 2.19 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have purchased 98,339 shares of company stock valued at $1,128,456. 22.67% of the stock is owned by company insiders.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.